First-in-Human Phase-1, Randomised, Double-Blinded, Placebo Controlled Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses, As Well As a Food Effect Study, of BF844 When Administered Orally to Healthy Adult Participants
Latest Information Update: 01 Oct 2024
At a glance
- Drugs BF 844 (Primary)
- Indications Usher syndromes
- Focus Adverse reactions; First in man
- Sponsors EyeXCel
- 01 Oct 2024 New trial record